Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EPS (Weighted Average and Diluted) (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.27 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 72.73% to -$0.27 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.03, a 42.72% increase, with the full-year FY2025 number at -$3.03, up 42.72% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.27 for Q4 2025 at Phathom Pharmaceuticals, up from -$0.4 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.27 in Q4 2025 to a low of -$1.56 in Q2 2024.
  • A 4-year average of -$1.08 and a median of -$1.19 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 85.71% in 2024, then surged 72.73% in 2025.
  • Phathom Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.33 in 2022, then decreased by 9.02% to -$1.45 in 2023, then soared by 31.72% to -$0.99 in 2024, then soared by 72.73% to -$0.27 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's EPS (Weighted Average and Diluted) are -$0.27 (Q4 2025), -$0.4 (Q3 2025), and -$1.05 (Q2 2025).